Country: Canada
Language: English
Source: Health Canada
RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE)
ABBVIE CORPORATION
M05BA07
RISEDRONIC ACID
150MG
TABLET
RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 150MG
ORAL
1
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0135301005; AHFS:
APPROVED
2017-08-03
_ACTONEL/ACTONEL DR (risedronate sodium) _ _Page 1 of 63_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ACTONEL® risedronate sodium tablets Tablets, 35 mg and 150 mg (as the hemi-pentahydrate), for oral use USP PR ACTONEL DR® risedronate sodium delayed-release tablets Delayed-release tablets, 35 mg (as the hemi-pentahydrate), for oral use Bisphosphonates (ATC Code: M05BA07) AbbVie Corporation 8401 Trans-Canada Highway St-Laurent, QC H4S 1Z1 Date of Initial Authorization: AUG 18, 1999 Date of Revision: NOV 3, 2022 Submission Control Number: 267898 _ _ _ACTONEL/ACTONEL DR (risedronate sodium) _ _Page 2 of 63_ RECENT MAJOR LABEL CHANGES 1 INDICATIONS 07/2022 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations 07/2022 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment 07/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 5 1 INDICATIONS ............................................................................................................. 5 1.1 Pediatrics .................................................................................................................. 6 1.2 Geriatrics .................................................................................................................. 6 2 CONTRAINDICATIONS ................................................................................................ 6 4 DOSAGE AND ADMINISTRATION ................................................................................ 6 4.1 Dosing Considerations ............................................................................................. 6 4.2 Recomme Read the complete document